• Kyodo, Reuters

  • SHARE

Fujifilm Holdings Corp. will continue clinical tests of its anti-flu drug Avigan, a candidate treatment for the novel coronavirus, beyond the initially scheduled end in June due to a lack of sufficient data, a company source said Monday.

Fujifilm planned to finish the clinical tests it started in March in Japan by the end of this month but has seen a delay as recent falls in the number of confirmed infections made it difficult to reach the enrollment target of 96 patients, the source said.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.

SUBSCRIBE NOW

PHOTO GALLERY (CLICK TO ENLARGE)